API | raclopride

raclopride Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Raclopride is a typical antipsychotic. It acts as a selective antagonist on D2 dopamine receptors. It has been used in trials studying Parkinson Disease. ^Wikipedia

Chemistry

SMILES: CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC
InChIKey: WAOQONBSWFLFPE-VIFPVBQESA-N
Mol. Mass: 347.24
ALogP: 2.92 Partition coefficient
ChEMBL Molecules:

raclopride

raclopride c 11

More Chemistry

Pharmacology

Mechanism of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

11c raclopride | raclopride | raclopride (11c) | raclopride c 11

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (15)

Approved Indications (1)

Parkinsonian Disorders

Experimental Indications - Clinical Trial Phases 1-4 (14)

Anhedonia (Phase 4)

Astrocytoma (Phase 1)

Brain Injuries, Traumatic (Phase 1)

Brain Neoplasms (Phase 1)

Cocaine-Related Disorders (Early Phase 1)

Depression (Phase 4)

Feeding and Eating Disorders (Phase 4)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Healthy Volunteers (Early Phase 1)

Obesity (Early Phase 1)

Oligodendroglioma (Phase 1)

Overweight (Early Phase 1)

Psychotic Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue